Jakavi, with the active ingredient Ruxolitinib, is a medication that falls into the category of Janus kinase (JAK) inhibitors. It is commonly used in the treatment of certain blood disorders, specifically myelofibrosis and polycythemia vera. Jakavi works by inhibiting the activity of Janus kinases, which are enzymes involved in the signaling pathways affecting blood cell production. Here is a detailed description of Jakavi (Ruxolitinib) 15 mg Tablets:

1. Mechanism of Action:

• Jakavi inhibits Janus kinases, primarily JAK1 and JAK2. By blocking these enzymes, Jakavi interferes with the signaling pathways that regulate blood cell production, particularly red blood cells, platelets, and white blood cells.

2. Indications:

• Jakavi is used in the treatment of:
  • Myelofibrosis: Jakavi is indicated for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
  • Polycythemia Vera: It may be prescribed for patients with polycythemia vera who have had an inadequate response to or cannot tolerate hydroxyurea.

3. Dosage:

• The dosage of Jakavi (Ruxolitinib) is determined by the healthcare provider based on the specific blood disorder being treated, the patient’s overall health, and other factors.
• It is typically taken orally in the form of tablets.

4. Administration:

• Jakavi tablets are usually taken twice daily, with or without food, as directed by the healthcare provider.
• The tablets should be swallowed whole with a glass of water.

5. Side Effects:

• Common side effects of Jakavi may include anemia, thrombocytopenia, fatigue, dizziness, and gastrointestinal symptoms such as nausea or diarrhea.
• Serious side effects can include an increased risk of infections, certain skin cancers, and changes in liver function.

6. Precautions:

• Jakavi should be used with caution in patients with a history of certain medical conditions, and regular monitoring of blood counts and liver function is typically conducted during treatment.
• Patients should inform their healthcare provider of any pre-existing conditions or medications they are taking.

7. Interactions:

• Jakavi may interact with certain medications, and patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking.

8. Monitoring:

• Regular monitoring by a healthcare provider is crucial to assess the effectiveness of the treatment, manage side effects, and watch for any complications.

Jakavi is an important therapeutic option for individuals with myelofibrosis or polycythemia vera, and its use should be under the supervision of a qualified healthcare professional. Patients are advised to follow their healthcare provider’s recommendations closely for optimal safety and efficacy.